Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 01 2021 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced that several key preclinical datasets
highlighting the potential of its lead product candidate,
IMM-1-104, will be presented at the upcoming AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics taking place virtually from October 7-10, 2021.
IMM-1-104 is designed to be a highly selective dual-MEK
inhibitor that further disrupts the kinase suppressor of RAS 1 and
2 (KSR1/2) for the treatment of advanced solid tumors in patients
harboring RAS mutant tumors. The Company anticipates submission of
an Investigational New Drug application (IND) for IMM-1-104 to the
U.S. Food and Drug Administration (FDA) in the first quarter of
2022.
The following posters featuring IMM-1-104 will be presented at
EORTC 21:
Title: |
|
IMM-1-104: a novel, oral, selective dual-MEK inhibitor that
displays broad antitumor activity and high tolerability across RAS
and RAF mutant tumors in vivo |
Poster #: |
|
P252 |
Presenter: |
|
Brett Hall, Ph.D., Chief Scientific Officer at Immuneering |
|
|
|
Title: |
|
Transcriptional effects in C26 tumor highlight mechanistic
aspects of a novel dual MEK inhibitor, IMM-1-104 |
Poster #: |
|
P254 |
Presenter: |
|
Sarah Kolitz, Ph.D., Vice President, Translational Medicine, at
Immuneering |
|
|
|
Title: |
|
Benchmarking the novel dual-MEK inhibitor, IMM-1-104,
head-to-head and in combination with sotorasib (AMG-510) in the MIA
PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model |
Poster #: |
|
P240 |
Presenter: |
|
Peter King, Ph.D., Vice President, Head of Discovery, at
Immuneering |
“We look forward to sharing data from multiple animal studies
that we believe demonstrate IMM-1-104’s potential for activity
against a wide range of RAS and RAF mutant tumors,” said Ben
Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer
of Immuneering. “Equally important is the tolerability profile that
we consistently observe across animal models. Taken together,
we believe these results indicate that IMM-1-104 achieves a
potentially attractive therapeutic index in a fundamentally new way
through deep cyclic inhibition of the MAPK pathway that is not
specific to any one mutation.”
“The transcriptomic data that we are presenting demonstrates
this novel mechanism. We are also presenting data showing synergy
with sotorasib in an animal model of KRAS G12C mutant pancreatic
cancer, and we believe IMM-1-104’s broad activity also means it has
the potential to overcome resistance frequently seen with
registered KRAS and MEK inhibitors,” added Dr. Zeskind.
Key Opinion Leader Event
Following the close of the conference, Immuneering management
will host a Key Opinion Leader Event, which will review the
presented data in greater detail and highlight its broader
application and potential. Event details are below:
Title: |
|
Better Medicines for MEK, RAS and Beyond Through Signaling
Dynamics |
Day/Time: |
|
October 12, 2021 from 11:30 am – 1:00 pm Eastern Time |
Presenters: |
|
Alexander Spira, MD, PHD, FACP, Director of the Virginia Cancer
Specialists Research Institute and US Oncology Research |
|
|
Anthony W. Tolcher, MD, FRCPC, FACP, FASCO, Director of
Clinical Research Founder and CEO of NEXT Oncology |
Registration: |
|
Better Medicines for MEK, RAS and Beyond Through Signaling
Dynamics Registration (onlinexperiences.com) |
About Immuneering
Corporation Immuneering
is a biopharmaceutical company with an emerging pipeline focused on
improving patient outcomes across a spectrum of debilitating
oncologic and neurologic diseases by applying its deep knowledge of
translational bioinformatics to every stage of the drug development
process. Immuneering has more than a decade of experience in
translational bioinformatics and generating insights into drug
mechanisms of action and patient treatment responses. Building on
this experience, Immuneering has developed a disease-agnostic
platform that enables the company to utilize human data, novel
biology and chemistry, and translational planning to create and
advance its wholly owned pipeline. Immuneering’s current
development programs in oncology are focused on providing potential
treatments for patients with solid tumors caused by mutations of
oncologic signaling pathways, including the MAPK pathway.
Immuneering’s lead product candidate, IMM-1-104, is designed to be
a highly selective dual-MEK inhibitor that further disrupts KSR for
the treatment of advanced solid tumors in patients harboring RAS
mutant tumors. Additionally, Immuneering has six other oncology
programs in the discovery stage that are designed to target either
the MAPK or mTOR pathway, and two neuroscience programs in the
discovery stage.
Forward-Looking Statements
This press release includes certain disclosures that contain
"forward-looking statements," including, without limitation,
statements regarding Immuneering’s progress toward drugs targeting
cancers driven by alterations that activate the RAS/MAPK pathway,
the treatment potential of IMM-1-104, and the timing of regulatory
filings for IMM-1-104 with the FDA. Forward-looking statements are
based on Immuneering’s current expectations and are subject to
inherent uncertainties, risks and assumptions that are difficult to
predict. Factors that could cause actual results to differ include,
but are not limited to, the risks inherent in oncology and
neuroscience drug development, including target discovery, target
validation, lead compound identification, lead compound
optimization, preclinical studies and clinical trials. These and
other risks and uncertainties are described more fully in the
section titled "Risk Factors" in the Company’s most recent Form
10-Q filed with the U.S. Securities and Exchange Commission (SEC)
as well as in Immuneering’s subsequent filings it makes with the
SEC. Forward-looking statements contained in this announcement are
made as of this date, and Immuneering undertakes no duty to update
such information except as required under applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Anne Marie FieldsManaging
DirectorRx Communications afields@rxir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024